All Posts By

Smartkarma Daily Briefs

Daily Brief Industrials: GS Engineering & Construction and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Top 20 Korean Construction Companies: Off-Balance Sheet Contingent Liabilities To Drive Lower Prices


Top 20 Korean Construction Companies: Off-Balance Sheet Contingent Liabilities To Drive Lower Prices

By Douglas Kim

  • We argue that the top 20 listed construction companies in Korea are likely to underperform KOSPI in 2024 mainly due to the excessive risks in the housing/commercial real estate sectors.
  • We expect the share prices of these 20 domestic construction companies to fall by at least 15%-20%+ on average in the next 6-12 months. 
  • On 2 January 2024, Financial Supervisory Service (FSS) announced that there will be new reporting requirements for PF loans of Korean construction companies starting 2023 annual reports.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: GS Engineering & Construction and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Top 20 Korean Construction Companies: Off-Balance Sheet Contingent Liabilities To Drive Lower Prices


Top 20 Korean Construction Companies: Off-Balance Sheet Contingent Liabilities To Drive Lower Prices

By Douglas Kim

  • We argue that the top 20 listed construction companies in Korea are likely to underperform KOSPI in 2024 mainly due to the excessive risks in the housing/commercial real estate sectors.
  • We expect the share prices of these 20 domestic construction companies to fall by at least 15%-20%+ on average in the next 6-12 months. 
  • On 2 January 2024, Financial Supervisory Service (FSS) announced that there will be new reporting requirements for PF loans of Korean construction companies starting 2023 annual reports.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Korea Stock Exchange Kospi Index, People’s Insurance (PICC), Bajaj Finance Ltd and more

By | Daily Briefs, Financials

In today’s briefing:

  • Korea’s Short Selling Ban to Stay, Likely Until EquiLend-Korean Version Launch
  • PICC’s (1339 HK)’s Implied Stub Plumbs New Lows As Interest Rate Cuts Bite
  • Bajaj Finance: Q3FY24 Preview


Korea’s Short Selling Ban to Stay, Likely Until EquiLend-Korean Version Launch

By Sanghyun Park

  • Local market information indicates potential collaboration between KRX, FSS, and KSD to create a Korean EquiLend, aiming to centralize the stock lending channel.
  • Unprecedented globally, President Yoon aims to centralize short selling. The challenge lies in mandating foreign investors to use Korea’s platform, necessitating a complex legal framework.
  • Despite the difficulty, local authorities are compelled to pursue this initiative, raising the likelihood of a Korean EquiLend. Developing strategic plans in response is imperative.

PICC’s (1339 HK)’s Implied Stub Plumbs New Lows As Interest Rate Cuts Bite

By David Blennerhassett


Bajaj Finance: Q3FY24 Preview

By Ankit Agrawal, CFA

  • Bajaj Finance Ltd (“BAF”) reported key performance metrics for Q3FY24. It reported strong growth, particularly in AUM which grew 7%+ QoQ and 35% YoY to reach INR 311,000cr.
  • Customer franchise grew 5%+ QoQ to reach 80.41mm, surpassing the 80mm mark. New loans booked grew to 9.86mm, a growth of 26% YoY and 15%+ QoQ.
  • The liability book also did well with deposits growing at around 6% QoQ and 35% YoY to reach INR 58,000cr.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Cloudbreak Pharma, Alteogen Inc and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation
  • Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility


Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation

By Ke Yan, CFA, FRM

  • Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.
  • In this note, we examine the company’s core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.
  • We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.

Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility

By Tina Banerjee

  • Alteogen Inc (196170 KS)‘s first proprietary recombinant human hyaluronidase liquid product, Tergase (ALT-BB4) is currently under approval process in Korea and is expected to receive approval in early 2024.  
  • Tergase is a stand-alone hyaluronidase product that can be used for the treatment of various medical conditions, such as pain relief, edema treatment, and hyaluronic acid filler removal.
  • Compared to commercially available animal-derived hyaluronidase products in the market, Tergase is a highly purified product of high-quality with very few impurities and an excellent side effect profile.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Taste Gourmet, Ola Electric, Fast Retailing, SJM Holdings and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Taste Gourmet (8371 HK): Q3 FY24 Preview and Future Catalysts
  • Ola Electric IPO: The Bull Case
  • Fast Retailing: Earnings Preview
  • Morning Views Asia: China Vanke , SJM Holdings


Taste Gourmet (8371 HK): Q3 FY24 Preview and Future Catalysts

By Sameer Taneja

  • We expect Q3 FY24 revenues/profits to be >40%/>70% YoY for Taste Gourmet (8371 HK) for their results in early February. 
  • Another catalyst we look forward to in CY24 is the main board listing on HKex. The timeline, we believe, should be in the second half of the year.
  • Trading at 6x PE with an 8.5% dividend yield and cash of 130 mn HKD, or about 21% of the market cap, is one of our top dividend gems.

Ola Electric IPO: The Bull Case

By Arun George

  • Ola Electric (1700674D IN), the largest Indian electric two-wheel vehicles (E2W) player, is seeking US$660 million from a primary raise along with a secondary raise at a US$7-8 billion valuation. 
  • Ola is the best-selling E2W brand in India in terms of monthly E2W registrations on the VAHAN Portal of the Ministry of Road Transport and Highways.
  • The bull case rests on rising market share in a growing market, a rapid growth phase, increasing gross margin and a favourable cash conversion cycle.   

Fast Retailing: Earnings Preview

By Oshadhi Kumarasiri

  • While domestic revenues may have slowed, Uniqlo’s domestic OP shows upside potential driven by gross margin growth and a gradual reduction in SG&A costs.
  • Meanwhile, we expect Uniqlo’s International business OP to surpass ¥75bn, driven by a rebound in China demand  and strong momentum in South Korea, SE Asia & Ocenia.
  • Thus, we see the upcoming earnings as a compelling opportunity for trading Fast Retailing (9983 JP).

Morning Views Asia: China Vanke , SJM Holdings

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Livent, Douzone Bizon, Korea Stock Exchange Kospi Index, Jio Financial Services, TSE Tokyo Price Index TOPIX, Amorepacific Corp, Samsung Electronics Pref Shares, People’s Insurance (PICC), Ola Electric, Lippo Malls Indonesia Retail Trust and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Allkem + Livent = Arcadium : Updated Expected Index Flows
  • KRX New Deal Index Rebalance Preview: Changes with Flow & Impact
  • Korea’s Short Selling Ban to Stay, Likely Until EquiLend-Korean Version Launch
  • NIFTY NEXT50 Index Rebalance Preview: Potential Adds Skyrocketing
  • New Year New NISA Accounts – It’s BIG, But Not so Big
  • Korean Holdcos Vs Opcos Gap Trading Opportunities in 1Q 2024
  • Gap Trades in Korean Prefs Vs Common Share Pairs in 1Q 2024
  • PICC’s (1339 HK)’s Implied Stub Plumbs New Lows As Interest Rate Cuts Bite
  • Ola Electric IPO: The Bull Case
  • Morning Views Asia: Indika Energy, Lippo Malls Indonesia Retail Trust, SK Hynix, Vedanta Resources


Allkem + Livent = Arcadium : Updated Expected Index Flows

By Travis Lundy

  • Allkem Ltd (AKE AU) saw its last day of trading on 21 December. There was large volume at the close as one major index provider gave it the boot. 
  • Another delayed their treatment at the last minute, and eliminated a cross-flow.
  • But there is still a lot of net buy flow tomorrow (3 Jan) and the next day in the US. Perhaps more than I expected. 

KRX New Deal Index Rebalance Preview: Changes with Flow & Impact

By Brian Freitas


Korea’s Short Selling Ban to Stay, Likely Until EquiLend-Korean Version Launch

By Sanghyun Park

  • Local market information indicates potential collaboration between KRX, FSS, and KSD to create a Korean EquiLend, aiming to centralize the stock lending channel.
  • Unprecedented globally, President Yoon aims to centralize short selling. The challenge lies in mandating foreign investors to use Korea’s platform, necessitating a complex legal framework.
  • Despite the difficulty, local authorities are compelled to pursue this initiative, raising the likelihood of a Korean EquiLend. Developing strategic plans in response is imperative.

NIFTY NEXT50 Index Rebalance Preview: Potential Adds Skyrocketing

By Brian Freitas

  • Nearing the end of the review period, we see 6 potential changes for the NSE Nifty Next 50 Index (NIFTYJR INDEX) using the current index methodology.
  • Estimated one-way turnover is 13.9% resulting in a one-way trade of INR 26.9bn. There will be more than 1.5x ADV to sell on nearly all deletes.
  • The potential adds have outperformed the potential deletes by 35% over the last two months and some stocks are looking extremely frothy.

New Year New NISA Accounts – It’s BIG, But Not so Big

By Travis Lundy

  • The Kishida administration put out a Doubling Asset-Based Income Plan in 2022. The goal? To get cash savings (corporate/individual) into growth assets and increase asset-based return contribution to income.
  • The goal included doubling the number of NISA accounts, and the amount invested in the next five years. On 1 January 2024, NEW NISA account contribution totals were trebled.
  • If accounts double, and contribution totals treble, and exemptions are now permanent, investment doubling is a quasi-certainty. The question is how it turns into income-producing assets. That’s MUCH tougher.

Korean Holdcos Vs Opcos Gap Trading Opportunities in 1Q 2024

By Douglas Kim

  • In this insight, we highlight the recent pricing gap divergences of the major Korean holdcos and opcos which could provide trading opportunities in 1Q 2024. 
  • We highlight 38 pair trades that involve Korean holdcos and opcos.
  • Of the 38 pair trades, 26 of them involved holdcos outperforming opcos in the past six months and 12 of them involved opcos outperforming holdcos in the same period.

Gap Trades in Korean Prefs Vs Common Share Pairs in 1Q 2024

By Douglas Kim

  • In this insight, we discuss numerous gap trades involving Korean preferred and common shares in 1Q 2024. 
  • The excessive gaps in the preferred and common shares of Kumho Petro Chemical, Amorepacific Corp, and Samsung Electronics could reverse in the next several months.
  • We see some attractive longer-term opportunities for Amorepacific, Doosan Fuel Cell, LG Electronics, and CJ Cheiljedang which have especially high discounts for the preferred shares versus their counterpart common shares.

PICC’s (1339 HK)’s Implied Stub Plumbs New Lows As Interest Rate Cuts Bite

By David Blennerhassett


Ola Electric IPO: The Bull Case

By Arun George

  • Ola Electric (1700674D IN), the largest Indian electric two-wheel vehicles (E2W) player, is seeking US$660 million from a primary raise along with a secondary raise at a US$7-8 billion valuation. 
  • Ola is the best-selling E2W brand in India in terms of monthly E2W registrations on the VAHAN Portal of the Ministry of Road Transport and Highways.
  • The bull case rests on rising market share in a growing market, a rapid growth phase, increasing gross margin and a favourable cash conversion cycle.   

Morning Views Asia: Indika Energy, Lippo Malls Indonesia Retail Trust, SK Hynix, Vedanta Resources

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief South Korea: Korea Stock Exchange Kospi Index, GS Engineering & Construction, Alteogen Inc and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Korea’s Short Selling Ban to Stay, Likely Until EquiLend-Korean Version Launch
  • Top 20 Korean Construction Companies: Off-Balance Sheet Contingent Liabilities To Drive Lower Prices
  • Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility


Korea’s Short Selling Ban to Stay, Likely Until EquiLend-Korean Version Launch

By Sanghyun Park

  • Local market information indicates potential collaboration between KRX, FSS, and KSD to create a Korean EquiLend, aiming to centralize the stock lending channel.
  • Unprecedented globally, President Yoon aims to centralize short selling. The challenge lies in mandating foreign investors to use Korea’s platform, necessitating a complex legal framework.
  • Despite the difficulty, local authorities are compelled to pursue this initiative, raising the likelihood of a Korean EquiLend. Developing strategic plans in response is imperative.

Top 20 Korean Construction Companies: Off-Balance Sheet Contingent Liabilities To Drive Lower Prices

By Douglas Kim

  • We argue that the top 20 listed construction companies in Korea are likely to underperform KOSPI in 2024 mainly due to the excessive risks in the housing/commercial real estate sectors.
  • We expect the share prices of these 20 domestic construction companies to fall by at least 15%-20%+ on average in the next 6-12 months. 
  • On 2 January 2024, Financial Supervisory Service (FSS) announced that there will be new reporting requirements for PF loans of Korean construction companies starting 2023 annual reports.

Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility

By Tina Banerjee

  • Alteogen Inc (196170 KS)‘s first proprietary recombinant human hyaluronidase liquid product, Tergase (ALT-BB4) is currently under approval process in Korea and is expected to receive approval in early 2024.  
  • Tergase is a stand-alone hyaluronidase product that can be used for the treatment of various medical conditions, such as pain relief, edema treatment, and hyaluronic acid filler removal.
  • Compared to commercially available animal-derived hyaluronidase products in the market, Tergase is a highly purified product of high-quality with very few impurities and an excellent side effect profile.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: Ola Electric, Bajaj Finance Ltd and more

By | Daily Briefs, India

In today’s briefing:

  • Ola Electric IPO: The Bull Case
  • Bajaj Finance: Q3FY24 Preview


Ola Electric IPO: The Bull Case

By Arun George

  • Ola Electric (1700674D IN), the largest Indian electric two-wheel vehicles (E2W) player, is seeking US$660 million from a primary raise along with a secondary raise at a US$7-8 billion valuation. 
  • Ola is the best-selling E2W brand in India in terms of monthly E2W registrations on the VAHAN Portal of the Ministry of Road Transport and Highways.
  • The bull case rests on rising market share in a growing market, a rapid growth phase, increasing gross margin and a favourable cash conversion cycle.   

Bajaj Finance: Q3FY24 Preview

By Ankit Agrawal, CFA

  • Bajaj Finance Ltd (“BAF”) reported key performance metrics for Q3FY24. It reported strong growth, particularly in AUM which grew 7%+ QoQ and 35% YoY to reach INR 311,000cr.
  • Customer franchise grew 5%+ QoQ to reach 80.41mm, surpassing the 80mm mark. New loans booked grew to 9.86mm, a growth of 26% YoY and 15%+ QoQ.
  • The liability book also did well with deposits growing at around 6% QoQ and 35% YoY to reach INR 58,000cr.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Ola Electric IPO: The Bull Case and more

By | Daily Briefs, ECM

In today’s briefing:

  • Ola Electric IPO: The Bull Case
  • Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation


Ola Electric IPO: The Bull Case

By Arun George

  • Ola Electric (1700674D IN), the largest Indian electric two-wheel vehicles (E2W) player, is seeking US$660 million from a primary raise along with a secondary raise at a US$7-8 billion valuation. 
  • Ola is the best-selling E2W brand in India in terms of monthly E2W registrations on the VAHAN Portal of the Ministry of Road Transport and Highways.
  • The bull case rests on rising market share in a growing market, a rapid growth phase, increasing gross margin and a favourable cash conversion cycle.   

Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation

By Ke Yan, CFA, FRM

  • Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.
  • In this note, we examine the company’s core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.
  • We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): China Property Developers In Distress – Weekly News & Announcements Tracker | Dec 29 -Jan 4 and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • China Property Developers In Distress – Weekly News & Announcements Tracker | Dec 29 -Jan 4, 2024
  • US Banks – Weekly Balance Sheets Show Risk Aversion Remains, New PMI Data Continues to Be Weak
  • There’s Something About Air Cargo (Part II)
  • Shroom Shmooz – Spotlight on Ketamine


China Property Developers In Distress – Weekly News & Announcements Tracker | Dec 29 -Jan 4, 2024

By Robert Ciemniak

  • This note is a weekly curated selection of Chinese news articles and company announcements focused on developers in distress
  • We look for their deals, updates, specific project progress news (‘local signals’), as well as relevant local research commentaries about the market
  • We do not verify the underlying data or provide any opinion, we only select and summarize the information; See direct links to sources

US Banks – Weekly Balance Sheets Show Risk Aversion Remains, New PMI Data Continues to Be Weak

By Daniel Tabbush

  • New data for US PMI shows a continued weak economy, which is not positive for bank lending prospects or for loan pricing. It is also not positive for credit metrics.
  • New weekly data for large US banks show risk aversion remains, with rising cash, but also dismal growth in loans at only 0.5% YoY in the most recent week.
  • Large time deposits continue to rise substantially at +110% YoY in most recent week, with cash rising too – the outlook for core net interest income is worsening.

There’s Something About Air Cargo (Part II)

By Mohshin Aziz

  • Air cargo rates from Hong Kong and Shanghai have plunged in the past week, as spot demand dries up post-Christmas rush and reverts to previous (lower) contractual rates      
  • Sea freight rates surged due to the Red Sea/Suez situation, with further increases expected. China to Europe air freight is highly competitive, potentially prompting a shift from sea freight
  • Chinese air carriers and Cathay Pacific will record stronger than expected 2H23 performance on air freight, and we think air freight should continue to be firm in 1Q24

Shroom Shmooz – Spotlight on Ketamine

By Water Tower Research

  • In this edition, we begin a series of spotlights on psychedelic therapies.
  • We start with ketamine, the first legalized psychoactive drug approved for the treatment of a mental health disorder—treatment-resistant depression (TRD)—being marketed under the brand name Spravato®.
  •  ‘Friends’ actor Matthew Perry’s untimely death last October has introduced ketamine to a broader market in an unfortunate way.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars